Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced new data presented at the 60th Annual Meeting of The Society of Thoracic Surgeons.
Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced new data presented at the 60th Annual Meeting of The Society of Thoracic Surgeons.